• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
HIV-1 Protease and Substrate Coevolution Validates the Substrate Envelope As the Substrate Recognition Pattern.HIV-1蛋白酶与底物的共同进化验证了底物包膜作为底物识别模式。
J Chem Theory Comput. 2012 Feb 14;8(2). doi: 10.1021/ct200668a.
2
Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution.耐药性 HIV-1 蛋白酶通过切割位点协同进化恢复功能动力学。
Evol Appl. 2015 Feb;8(2):185-98. doi: 10.1111/eva.12241. Epub 2015 Jan 11.
3
HIV-1 protease-substrate coevolution in nelfinavir resistance.奈非那韦耐药中HIV-1蛋白酶与底物的共同进化
J Virol. 2014 Jul;88(13):7145-54. doi: 10.1128/JVI.00266-14. Epub 2014 Apr 9.
4
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.评估底物-囊泡假说:设计用于抵抗耐药性的新型 HIV-1 蛋白酶抑制剂的结构分析。
J Virol. 2010 May;84(10):5368-78. doi: 10.1128/JVI.02531-09. Epub 2010 Mar 17.
5
Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope.HIV-1 蛋白酶中优先底物识别的动力学:重新定义底物信封。
J Mol Biol. 2011 Jul 22;410(4):726-44. doi: 10.1016/j.jmb.2011.03.053.
6
Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.1型人类免疫缺陷病毒核衣壳-p1裂解位点与病毒蛋白酶中V82A耐药突变协同进化的结构基础
J Virol. 2004 Nov;78(22):12446-54. doi: 10.1128/JVI.78.22.12446-12454.2004.
7
Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease.HIV-1蛋白酶耐药性中Gag底物协同进化的结构基础及远端效应
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):15993-8. doi: 10.1073/pnas.1414063111. Epub 2014 Oct 29.
8
Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate.奈非那韦耐药性HIV-1蛋白酶与p1-p6底物的共同进化
Virology. 2006 Apr 10;347(2):405-9. doi: 10.1016/j.virol.2005.11.049. Epub 2006 Jan 20.
9
Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease.九种晶体结构确定了 MDR HIV-1 蛋白酶的底物包络。
Protein J. 2011 Mar;30(3):173-83. doi: 10.1007/s10930-011-9316-2.
10
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.一种基于底物的新型HIV-1蛋白酶抑制剂耐药机制。
PLoS Med. 2007 Jan;4(1):e36. doi: 10.1371/journal.pmed.0040036.

引用本文的文献

1
Dynamic Allostery: Evolution's Double-Edged Sword in Protein Function and Disease.动态变构:蛋白质功能与疾病中进化的双刃剑
J Mol Biol. 2025 Apr 24:169175. doi: 10.1016/j.jmb.2025.169175.
2
[Not Available].[无可用内容]
Acta Pharm Sin B. 2024 Jan;14(1):87-109. doi: 10.1016/j.apsb.2023.08.004. Epub 2023 Aug 9.
3
Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance.HIV-1 对第五代蛋白酶抑制剂耐药性的选择揭示了两种独立的高耐药水平的途径。
Elife. 2023 Mar 15;12:e80328. doi: 10.7554/eLife.80328.
4
Sequence dependencies and biophysical features both govern cleavage of diverse cut-sites by HIV protease.序列依赖性和生物物理特征共同控制 HIV 蛋白酶对多种切割位点的切割。
Protein Sci. 2022 Jul;31(7):e4366. doi: 10.1002/pro.4366.
5
Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.直接作用抗病毒药物及其他药物的耐药性规避药物设计策略。
Chem Rev. 2021 Mar 24;121(6):3238-3270. doi: 10.1021/acs.chemrev.0c00648. Epub 2021 Jan 7.
6
A synergy of activity, stability, and inhibitor-interaction of HIV-1 protease mutants evolved under drug-pressure.在药物压力下进化的 HIV-1 蛋白酶突变体的活性、稳定性和抑制剂相互作用的协同作用。
Protein Sci. 2021 Mar;30(3):571-582. doi: 10.1002/pro.4013. Epub 2020 Dec 22.
7
HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites.HIV-1 蛋白酶利用双特异性 S2/S2' 亚基来优化两种靶位点的切割。
J Mol Biol. 2018 Dec 7;430(24):5182-5195. doi: 10.1016/j.jmb.2018.10.022. Epub 2018 Nov 7.
8
Interdependence of Inhibitor Recognition in HIV-1 Protease.HIV-1蛋白酶中抑制剂识别的相互依赖性
J Chem Theory Comput. 2017 May 9;13(5):2300-2309. doi: 10.1021/acs.jctc.6b01262. Epub 2017 Apr 11.
9
Structural and molecular analysis of a protective epitope of Lyme disease antigen OspA and antibody interactions.莱姆病抗原OspA保护性表位的结构与分子分析及抗体相互作用
J Mol Recognit. 2017 May;30(5). doi: 10.1002/jmr.2595. Epub 2016 Nov 16.
10
Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution.耐药性 HIV-1 蛋白酶通过切割位点协同进化恢复功能动力学。
Evol Appl. 2015 Feb;8(2):185-98. doi: 10.1111/eva.12241. Epub 2015 Jan 11.

本文引用的文献

1
Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope.HIV-1 蛋白酶中优先底物识别的动力学:重新定义底物信封。
J Mol Biol. 2011 Jul 22;410(4):726-44. doi: 10.1016/j.jmb.2011.03.053.
2
Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.聚乙二醇干扰素联合利巴韦林治疗患者丙型肝炎病毒多聚蛋白位点的共同进化。
J Virol. 2011 Apr;85(7):3649-63. doi: 10.1128/JVI.02197-10. Epub 2011 Jan 19.
3
Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.对 HCV NS3/4A 抑制剂的耐药性由底物识别与抑制剂结合的平衡决定。
Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):20986-91. doi: 10.1073/pnas.1006370107. Epub 2010 Nov 17.
4
Coevolution and HBV drug resistance.协同进化与乙肝病毒耐药性
Antivir Ther. 2010;15(3 Pt B):505-15. doi: 10.3851/IMP1515.
5
Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.1型人类免疫缺陷病毒蛋白酶相关切割位点突变增强抑制剂耐药性。
J Virol. 2009 Nov;83(21):11027-42. doi: 10.1128/JVI.00628-09. Epub 2009 Aug 12.
6
Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease.活性位点D25N突变对成熟HIV-1蛋白酶的结构、稳定性及配体结合的影响
J Biol Chem. 2008 May 9;283(19):13459-70. doi: 10.1074/jbc.M708506200. Epub 2008 Feb 15.
7
HIV drug development: the next 25 years.艾滋病病毒药物研发:未来25年
Nat Rev Drug Discov. 2007 Dec;6(12):959-66. doi: 10.1038/nrd2336.
8
Hepatitis C virus--biology, host evasion strategies, and promising new therapies on the horizon.丙型肝炎病毒——生物学特性、宿主逃避策略及即将出现的有前景的新疗法
Med Res Rev. 2007 May;27(3):353-73. doi: 10.1002/med.20063.
9
Rationale and uses of a public HIV drug-resistance database.一个公共艾滋病毒耐药性数据库的基本原理及用途。
J Infect Dis. 2006 Sep 15;194 Suppl 1(Suppl 1):S51-8. doi: 10.1086/505356.
10
Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate.奈非那韦耐药性HIV-1蛋白酶与p1-p6底物的共同进化
Virology. 2006 Apr 10;347(2):405-9. doi: 10.1016/j.virol.2005.11.049. Epub 2006 Jan 20.

HIV-1蛋白酶与底物的共同进化验证了底物包膜作为底物识别模式。

HIV-1 Protease and Substrate Coevolution Validates the Substrate Envelope As the Substrate Recognition Pattern.

作者信息

Ozen Ayşegül, Haliloğlu Türkan, Schiffer Celia A

机构信息

Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, United States.

Polymer Research Center, Bogazici University, Bebek, Istanbul, Turkey.

出版信息

J Chem Theory Comput. 2012 Feb 14;8(2). doi: 10.1021/ct200668a.

DOI:10.1021/ct200668a
PMID:24348205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3862175/
Abstract

Drug resistance of HIV-1 protease alters the balance in the molecular recognition events in favor of substrate processing versus inhibitor binding. To develop robust inhibitors targeting ensembles of drug-resistant variants, the code of this balance needs to be cracked. For this purpose, the principles governing the substrate recognition are required to be revealed. Previous crystallographic studies on the WT protease-substrate complexes showed that the substrates have a conserved consensus volume in the protease active site despite their low sequence homology. This consensus volume is termed as the substrate envelope. The substrate envelope was recently reevaluated by taking the substrate dynamics into account, and the dynamic substrate envelope was reported to better define the substrate specificity for HIV-1 protease. Drug resistance occurs mostly through mutations in the protease, occasionally accompanied by cleavage site mutations. In this study, three coevolved protease-substrate complexes (NC-p1, p1-p6, and p1-p6) were investigated for structural and dynamic properties by molecular modeling and dynamics simulations. The results show the substrate envelope is preserved by these cleavage site mutations in the presence of drug-resistance mutations in the protease, if not enhanced. This study on the conformational and mutational ensembles of protease-substrate complexes validates the substrate envelope as the substrate recognition motif for HIV-1 protease. The substrate envelope hypothesis allows for the elucidation of possible drug resistance mutation patterns in the polyprotein cleavage sites.

摘要

HIV-1蛋白酶的耐药性改变了分子识别事件中的平衡,有利于底物加工而非抑制剂结合。为了开发针对耐药变体群体的强效抑制剂,需要破解这种平衡的密码。为此,需要揭示底物识别的原理。先前对野生型蛋白酶-底物复合物的晶体学研究表明,尽管底物的序列同源性较低,但它们在蛋白酶活性位点具有保守的共有体积。这个共有体积被称为底物包膜。最近通过考虑底物动力学对底物包膜进行了重新评估,据报道动态底物包膜能更好地定义HIV-1蛋白酶的底物特异性。耐药性主要通过蛋白酶中的突变发生,偶尔伴有切割位点突变。在本研究中,通过分子建模和动力学模拟研究了三种共同进化的蛋白酶-底物复合物(NC-p1、p1-p6和p1-p6)的结构和动力学性质。结果表明,在蛋白酶存在耐药性突变的情况下,这些切割位点突变会保留底物包膜,甚至可能增强。这项对蛋白酶-底物复合物构象和突变群体的研究验证了底物包膜是HIV-1蛋白酶的底物识别基序。底物包膜假说有助于阐明多蛋白切割位点可能的耐药突变模式。